In lung cancer, the use of the Cobas Epidermal Growth Factor Receptor (EGFR) Mutation Test v2 (Roche, Basel Switzerland) is approved for the detection of EGFR variants by cfDNA analysis by the Food and Drug Administration (FDA) for treatment selection [10–12]. The gene discussed is EGFR; the disease is lung cancer.